DMAC Starts Phase 2 Trial
DMAC DiaMedica Therapeutics announces first patients dosed in Phase 2 trial of DM199 for the treatment of fetal growth restriction
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.